NASDAQ:VBLT
Delisted
Vascular Biogenics Ltd. Stock News
$0.156
+0 (+0%)
At Close: Jan 12, 2024
Vascular Biogenics (VBLT) Reports Q4 Loss, Lags Revenue Estimates
01:25pm, Wednesday, 23'rd Mar 2022 Zacks Investment Research
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -50% and 2%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Vascular Biogenics (VBLT) Reports Q4 Loss, Lags Revenue Estimates
10:32am, Wednesday, 23'rd Mar 2022
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -50% and 2%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
UPDATE -- VBL Therapeutics to Report Year-End 2021 Financial Results on March 23
01:57pm, Monday, 14'th Mar 2022 GlobeNewswire Inc.
TEL AVIV, Israel and NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for d
VLB Therapeutics to Report Year-End 2021 Financial Results on March 23
12:00pm, Monday, 14'th Mar 2022 GlobeNewswire Inc.
TEL AVIV, Israel and NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for d
UPDATE -- VBL Therapeutics to Report Year-End 2021 Financial Results on March 23
09:57am, Monday, 14'th Mar 2022
TEL AVIV, Israel and NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for dif
VLB Therapeutics to Report Year-End 2021 Financial Results on March 23
08:00am, Monday, 14'th Mar 2022
TEL AVIV, Israel and NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for dif
VBL Therapeutics to Participate at March Investor Conferences
08:00am, Thursday, 03'rd Mar 2022
TEL AVIV, Israel and NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-t
Regenxbio (RGNX) Q4 Earnings and Revenues Beat Estimates
10:45pm, Tuesday, 01'st Mar 2022 Zacks Investment Research
Regenxbio (RGNX) delivered earnings and revenue surprises of 55.84% and 29.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09:05pm, Tuesday, 15'th Feb 2022 GlobeNewswire Inc.
TEL AVIV, Israel and NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-
Vascular Biogenics (VBLT) Investor Presentation - Slideshow
08:03pm, Monday, 14'th Feb 2022 Seeking AlphaVBL Therapeutics to Participate in the Guggenheim Oncology Conference and the 2022 BIO CEO & Investor Conference
08:00am, Wednesday, 02'nd Feb 2022
TEL AVIV, Israel and NEW YORK, Feb. 02, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-tr
VBL Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference
01:10pm, Thursday, 06'th Jan 2022 GlobeNewswire Inc.
TEL AVIV, Israel and NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat
VBL Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference
08:10am, Thursday, 06'th Jan 2022
TEL AVIV, Israel and NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat m
VBL Therapeutics Selected for €17.5 Million of Funding from Horizon Europe EIC Accelerator Program
12:30pm, Monday, 20'th Dec 2021 GlobeNewswire Inc.
VBL is among only 9% of companies across industries selected by the EIC Accelerator
Reata (RETA) Falls on Negative Advisory Committee Outcome
04:18pm, Thursday, 09'th Dec 2021 Zacks Investment Research
An FDA advisory committee believes Reata's (RETA) bardoxolone study data does not support the effectiveness of the candidate in slowing the progression of CKD in patients with Alport syndrome.
